Merck's LIPFENDRA (enlicitide), the first FDA-approved oral PCSK9 inhibitor, approved 16 July 2026 at a list price of $315 for a 30-day supply. Amgen's Repatha (evolocumab) is already available for ...
By Qu Liu. The Miner School of Computer and Information Sciences is proud to announce a Dissertation Proposal by Qu Liu titled "Efficient and Adaptive Online Learning M ...
Dan Kueter stated, "The ineffective IDR process that's associated with the No Surprises Act is being exploited by select providers and select geographies," noting that it contributes 50 to 100 basis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results